Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

An in vivo CRISPR screen identifies stepwise genetic dependencies of metastatic progression

ABSTRACT: An in vivo CRISPR screen identifies stepwise genetic dependencies of metastatic progression

PROVIDER: PRJNA577413 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10273500.fastq.gz	Fastqsanger.gz
	SRR10273501.fastq.gz	Fastqsanger.gz
	SRR10273502.fastq.gz	Fastqsanger.gz
	SRR10273503.fastq.gz	Fastqsanger.gz
	SRR10273504.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 26

Similar Datasets

An in vivo CRISPR screen identifies stepwise genetic dependencies of metastatic progression

Project description:In vivo genome-wide loss-of-function CRISPR screen identifies critical genes required for individual steps of the metastatic cascade in human CTC-derived xenografts, suggesting novel drivers and vulnerabilities of breast cancer metastasis.

2022-01-27 | GSE138813 | GEO

In vivo CRISPR/Cas9 screen to identify candidate therapeutic gene targets to enhance docetaxel efficacy in prostate cancer

Project description:Docetaxel chemotherapy in metastatic prostate cancer offers only a modest survival benefit due to emerging resistance. To identify candidate therapeutic gene targets, we applied a murine prostate cancer orthograft model that recapitulates clinical invasive prostate cancer in a genome-wide CRISPR/Cas9 screen under docetaxel treatment pressure.

2020-10-07 | E-MTAB-9482 | biostudies-arrayexpress

A virally encoded high resolution screen of cytomegalovirus host dependencies

Project description:A virally encoded high resolution screen of cytomegalovirus host dependencies

| PRJNA1034526 | ENA

Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma

Project description:Despite progress in intensification of therapy, outcomes for patients with metastatic osteosarcoma (OS) have not improved in thirty years. We developed a system that enables preclinical screening of compounds against metastatic OS cells in the context of the native lung microenvironment. Using this strategy to screen a library of epigenetically-targeted compounds, we identified inhibitors of CDK12 to be most effective, reducing OS cell outgrowth in the lung by >90% at sub-micromolar doses. CDK12 inhibition led to defects in transcription elongation in a gene length- and expression-dependent manner. These effects were accompanied by defects in RNA processing and altered the expression of genes involved in transcription regulation and the DNA damage response. We further identify OS models that differ in their sensitivity to CDK12 inhibition in the lung and provide evidence that upregulated MYC levels may mediate these differences. Our studies provide a framework for rapid preclinical testing of compounds with anti-metastatic activity and highlight CDK12 as a potential therapeutic target in osteosarcoma.

2019-06-06 | GSE132233 | GEO

Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma

Project description:Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma

| PRJNA546568 | ENA

Epigenetic and metabolic reprogramming by HDAC inhibition targets NRF2-active tumors [CRISPR Screen]

Project description:To identify NRF2-specific dependencies in chromatin regulation, we performed a focused genetic screen mouse LUAD cell lines with or without knock-out of KEAP1.

2023-03-30 | GSE220831 | GEO

CRISPR screen

Project description:CRISPR screen

| OEX00023089 | NODE

HMGA2 project, CRISPR screen

Project description:HMGA2 project, CRISPR screen

| PRJNA718268 | ENA

FaDu RT CRISPR Screen

Project description:FaDu RT CRISPR Screen

| PRJNA612971 | ENA

Glioblastoma CRISPR Screen

Project description:This is an in vitro genome-wide CRISPR/cas9 screen in human glioblastoma stem cells, screening for genes essential for survival of these cells. These cells express cas9 and have been transfected with a guide RNA library causing gene knockouts. We will analyse the sequencing data for depletion of guide RNAs.

| EGAS00001001519 | EGA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data